Triple-Negative Breast Cancer (TNBC) – Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033

Triple-Negative Breast Cancer (TNBC) Market Outlook

Thelansis’s “Triple-Negative Breast Cancer (TNBC) Market Outlook, Epidemiology, Competitive Landscape, and Market Forecast Report – 2023 To 2033" covers disease overview, epidemiology, drug utilization, prescription share analysis, competitive landscape, clinical practice, regulatory landscape, patient share, market uptake, market forecast, and key market insights under the potential Triple-Negative Breast Cancer treatment modalities options for eight major markets (USA, Germany, France, Italy, Spain, UK, Japan, and China).

Triple-Negative Breast Cancer (TNBC) Overview

Triple-negative breast cancer (TNBC) is a heterogeneous disease encompassing a variety of biomarkers or genomic signatures; it accounts for 12% of all breast cancers in the USA. 1- and 2- year survival rates are 75% and 55%, respectively. Prognosis is poor in the advanced stages – median survival of 13.3 months following diagnosis of metastatic TNBC. Emerging therapies are expected to drive patient stratification for biomarker-defined and pathway-specific (subtyping) patient subgroups - an opportunity for a novel agent in relevant specific segments. TNBC is a clinicopathologic, not intrinsic (genomically defined) subgroup, as neither overexpressing ER and PR nor being HER2+ (IHC and/or FISH). Neither hormonal (endocrine) nor HER2-targeted therapies are indicated potential for FastTrack/ breakthrough designation with promising outcomes in the biomarker-driven patient segment. Several PARP inhibitors are in trials; veliparib+carboplatin followed by chemotherapy showed pCR: 52% vs 26% (chemotherapy alone) 40% of TNBC show overexpression of GPNMB; impressive activity with glembatumumab, a GPNMB-targeting AD Biomarker-driven segments have been identified within TNBC, with POC. A better understanding of these would enable personalized treatment with improved patient outcomes. p53, PTEN, and PIK3CA are most frequently mutated in TNBC (>10%).

• The mean annual incidence of triple-negative breast cancer (TNBC) across SEAs was 13.7 per 100,000 women.

Geography Covered:

North America- the United States and Canada

Europe- EU5 (Germany, France, Italy, Spain, and the United Kingdom)

Other countries- Japan & China

Study Period: 2023-2033

Current Clinical Practice and Treatment Algorithm

This section of the study covers country-specific current clinical practice, the standard of care, and significant limitations around addressing the unmet needs. Retrospective analysis and bench-marking of clinical study outcomes are presented in terms of Pre-treatment & post-treatment clinical and demographic patient characteristics. Essentially, this section will cover the evolution of the current competitive landscape and its impact on the future treatment paradigm.

KOL Insights:

KOLs across 8 MM markets from the center of Excellence/ Public/ Private hospitals participated in the study. Insights around current treatment landscape, epidemiology, clinical characteristics, future treatment paradigm, and Unmet needs

Market Forecast: Patient Based Forecast Model (MS. Excel Based Automated Dashboard)

- Data Inputs with sourcing

- Market Event and Product Event

- Country-specific Forecast Model

- Market uptake and patient share uptake

- Attribute Analysis

- Analog Analysis

- Disease burden and pricing scenario

- Summary and Insights

NPV/ IRR Calculator-

Optimization of cash flow/ revenue flow concerning all fixed and variable investments throughout the product development process. The rate of return on an investment is a critical indicator to ensure the profitability and break-even of the project.

Competitive Landscape:

The competitive landscape includes country-specific approved as well as pipeline therapies. Any asset/product-specific designation or review such as Orphan drug designation, Fast track, Priority Review, Breakthrough Therapy Designation, Rare Pediatric Disease Designation, and Accelerated Approval are tracked and supplemented with analyst commentary.

Clinical Trial Assessment-

Detailed clinical trial data analysis and critical product positioning include trial design, primary outcomes, secondary outcomes, dosing and schedules, inclusion and exclusion criteria, recruitment status and essentially covers the reported adverse events. Majorly the trial analysis helps determine the potential of the critical assets and their probable filing and launch date.

Unmet Medical Needs Overview-

This report presents the most important clinical unmet needs in the treatment, according to Thelansis research and analysis. Other essential unmet needs identified through our study include decreased cost burden on patients, improved administration convenience, and improved patient compliance.

Visit our social media pages: